These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 19248218)

  • 41. Patterns of progression in malignant glioma following anti-VEGF therapy: perceptions and evidence.
    Wick W; Wick A; Weiler M; Weller M
    Curr Neurol Neurosci Rep; 2011 Jun; 11(3):305-12. PubMed ID: 21279815
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Anti-angiogenesis treatment for brain tumors: present and future].
    Takano S; Matsumura A
    No Shinkei Geka; 2006 Jul; 34(7):657-78. PubMed ID: 16841703
    [No Abstract]   [Full Text] [Related]  

  • 43. Bevacizumab and irinotecan for recurrent oligodendroglial tumors.
    Chamberlain MC
    Neurology; 2010 Jan; 74(2):181. PubMed ID: 20065257
    [No Abstract]   [Full Text] [Related]  

  • 44. Bevacizumab-induced diffusion restriction in patients with glioma: tumor progression or surrogate marker of hypoxia?
    Rieger J; Bähr O; Ronellenfitsch MW; Steinbach J; Hattingen E
    J Clin Oncol; 2010 Sep; 28(27):e477; author reply e478. PubMed ID: 20585096
    [No Abstract]   [Full Text] [Related]  

  • 45. Bevacizumab for recurrent hemangioendothelioma.
    Trautmann K; Bethke A; Ehninger G; Folprecht G
    Acta Oncol; 2011 Jan; 50(1):153-4. PubMed ID: 20950228
    [No Abstract]   [Full Text] [Related]  

  • 46. Outcome of discontinuing bevacizumab prior to malignant glioma progression.
    Sherman WJ; Raizer JJ; Grimm SA
    J Neurooncol; 2013 Jan; 111(1):87-9. PubMed ID: 23065093
    [No Abstract]   [Full Text] [Related]  

  • 47. The paradoxical effect of bevacizumab in the therapy of malignant gliomas.
    Thompson EM; Frenkel EP; Neuwelt EA
    Neurology; 2011 Jan; 76(1):87-93. PubMed ID: 21205697
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Reversible posterior leukoencephalopathy syndrome associated to bevacizumab].
    Ortiz-Lopez EM; Gonzalez-Nieto JA; Rojas-Marcos I; Blanco-Ollero A
    Rev Neurol; 2010 Jul; 51(2):117-8. PubMed ID: 20602317
    [No Abstract]   [Full Text] [Related]  

  • 49. Case report of interstitial nephritis induced by bevacizumab therapy for glioblastoma multiforme.
    Lomax AJ; Hill PA; Ashley DM
    J Oncol Pharm Pract; 2013 Dec; 19(4):365-8. PubMed ID: 23235917
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Angiogenesis inhibition in neurooncology. A very promising therapy strategy for malignant glioma].
    Tabatabai G; Stupp R
    Nervenarzt; 2010 Aug; 81(8):936-9. PubMed ID: 20669004
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Bevacizumab for recurrent alkylator-refractory anaplastic oligodendroglioma.
    Chamberlain MC; Johnston S
    Cancer; 2009 Apr; 115(8):1734-43. PubMed ID: 19197992
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Angiogenic inhibition in high-grade gliomas: past, present and future.
    Jo J; Schiff D; Purow B
    Expert Rev Neurother; 2012 Jun; 12(6):733-47. PubMed ID: 22650175
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Bevacizumab for Patients with Recurrent Gliomas Presenting with a Gliomatosis Cerebri Growth Pattern.
    Burger MC; Mildenberger IC; Wagner M; Mittelbronn M; Steinbach JP; Bähr O
    Int J Mol Sci; 2017 Mar; 18(4):. PubMed ID: 28353668
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Fractal analysis of the susceptibility weighted imaging patterns in malignant brain tumors during antiangiogenic treatment: technical report on four cases serially imaged by 7 T magnetic resonance during a period of four weeks.
    Di Ieva A; Matula C; Grizzi F; Grabner G; Trattnig S; Tschabitscher M
    World Neurosurg; 2012; 77(5-6):785.e11-21. PubMed ID: 22120276
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Efficacy of bevacizumab therapy in recurrent malignant gliomas in relation to the prior recurrence pattern or tumor location.
    Matsuda M; Ishikawa E; Yamamoto T; Akutsu H; Takano S; Matsumura A
    J Clin Neurosci; 2017 Jun; 40():115-119. PubMed ID: 28246006
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Insights into pharmacotherapy of malignant glioma in adults.
    Salvati M; D'Elia A; Formichella AI; Frati A
    Expert Opin Pharmacother; 2009 Oct; 10(14):2279-90. PubMed ID: 19663635
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Enigma of a rapid introduction of antiangiogenic therapy with bevacizumab in glioblastoma: a new era in the treatment of malignant brain tumours?
    Henriksson R; Bergström P; Johansson M; Sandström M
    Acta Oncol; 2009; 48(1):6-8. PubMed ID: 18932097
    [No Abstract]   [Full Text] [Related]  

  • 58. Patterns of relapse and prognosis after bevacizumab failure in recurrent glioblastoma.
    Chamberlain MC; Lassman AB; Iwamoto FM
    Neurology; 2010 Apr; 74(15):1239-41. PubMed ID: 20385899
    [No Abstract]   [Full Text] [Related]  

  • 59. Has bevacizumab (Avastin) given extra therapeutic gain in metastatic colorectal cancer and malignant brain gliomas? Systematic review answering this question.
    Koukourakis GV
    Recent Pat Inflamm Allergy Drug Discov; 2012 Jan; 6(1):70-7. PubMed ID: 22022926
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Lower-grade gliomas: the wrong target for bevacizumab.
    Schiff D; de Groot JF
    Neuro Oncol; 2018 Nov; 20(12):1559-1560. PubMed ID: 30418659
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.